SCHEMBL687664

SCHEMBL687664

CCOC(=O)c1ccc(CN)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.67
LMNA P02545 1/20 0.67
CYP1A2 P05177 1/20 0.67
CYP3A4 P08684 1/20 0.67
MAOA P21397 1/20 0.67
CA1 P00915 3/20 0.63
CA2 P00918 3/20 0.63
CA12 O43570 2/20 0.63
CA7 P43166 2/20 0.63
CA9 Q16790 2/20 0.63
CA14 Q9ULX7 2/20 0.63
ESR1 P03372 1/20 0.63
ESR2 Q92731 1/20 0.63
SMN1; SMN2 Q16637 3/20 0.58
STS P08842 1/20 0.56
HTT P42858 5/20 0.54
HPGD P15428 4/20 0.54
KMT2A Q03164 3/20 0.51
ALDH1A1 P00352 2/20 0.51
MEN1 O00255 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL367399 0.98 LOXL2 (0.65) LOXL2LMNACYP1A2CYP3A4MAOA
Phosphoric Acid SCHEMBL27419957 0.93 LOXL2 (0.59) LOXL2LMNACYP1A2CYP3A4MAOA
Phosphoric Acid SCHEMBL27419958 0.93 LOXL2 (0.59) LOXL2LMNACYP1A2CYP3A4MAOA
Sulfuric Acid SCHEMBL8295634 0.93 LOXL2 (0.59) LOXL2LMNACYP1A2CYP3A4MAOA
SCHEMBL31868 0.92 LMNA (0.57) LOXL2LMNACYP1A2CYP3A4MAOA
SCHEMBL128190 0.86 CA1 (0.70) LMNACYP1A2CYP3A4MAOACA1
SCHEMBL87450 0.85 CA1 (0.83) LMNACYP1A2CYP3A4MAOACA1
SCHEMBL5734417 0.85 LMNA (0.68) LMNACYP1A2CYP3A4MAOACA1
SCHEMBL12199135 0.84 CA1 (0.68) LMNACYP1A2CYP3A4MAOACA1
Hydrochloric Acid SCHEMBL9261439 0.84 LMNA (0.66) LMNACYP1A2CYP3A4MAOACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107096036-B Preparation method and application of pH-sensitive hyaluronic acid-doxorubicin nano prodrug 武汉理工大学 2020-01-14 CN claimed
EP-4638433-A1 NAMPT MODULATORS Cytokinetics, Inc. (US) 2025-10-29 EP disclosed
US-20250163049-A1 FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS EXELIXIS INC (US) 2025-05-22 US disclosed
EP-4472946-A1 FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS Exelixis, Inc. (US) 2024-12-11 EP disclosed
US-20240279215-A1 NAMPT MODULATORS CYTOKINETICS, INCORPORATED 2024-08-22 US disclosed
WO-2024137981-A1 NAMPT MODULATORS CYTOKINETICS, INCORPORATED (US) 2024-06-27 WO disclosed
CN-117285504-A Amino phenylacetamide derivative and preparation method and application thereof 桂林医学院 2023-12-26 CN disclosed
WO-2023148643-A1 FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-08-10 WO disclosed
WO-2023148643-A1 FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-08-10 WO disclosed
US-11530226-B2 Azepane inhibitors of menin-MLL interaction JANSSEN PHARMACEUTICA NV (BE) 2022-12-20 US disclosed
US-4904671-A ANTIARTHRITIC AGENTS; PLATELET ACTIVATING FACTOR PFIZER INC. (US) 1990-02-27 US disclosed
EP-0330327-A2 Dihydropyridines, their preparation and their use as PAF-antagonists Pfizer Limited (GB) 1989-08-30 EP disclosed
EP-0225718-A2 Dopamine-beta-hydroxylase inhibitors SMITHKLINE BECKMAN CORPORATION (US) 1987-06-16 EP disclosed
US-4628059-A TRIAZOLES SMITHKLEIN BECKMAN CORPORATION (US) 1986-12-09 US disclosed
US-4496447-A PHOTOPOLYMERIZATION OF UNSATURATED COMPOUNDS AND FOR CURING PRINTING INKS MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 1985-01-29 US disclosed
US-4374984-A Aromatic-aliphatic ketones useful as photoinitiators MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1983-02-22 US disclosed
US-4275184-A HYDROSILATION OF POLYDIMETHYL SILOXANE RHONE-POULENC INDUSTRIES (FR) 1981-06-23 US disclosed
US-4213914-A ADDITION-CONDENSATION COPOLYMERS RHONE-POULENC INDUSTRIES (FR) 1980-07-22 US disclosed
US-4147711-A Ethylenic silicon compounds and thermoplastic elastomers obtained therefrom RHONE-POULENC INDUSTRIES (FR) 1979-04-03 US disclosed
US-4088670-A P-(DIMETHYLVINYLSILYL-METHOXY)-BENZOYL CHLORIDE FROM DIMETHYLVINYL-CHLOROMETHYLSILANE AND A P-HYDROXYBENZOIC ACID RHONE-POULENC INDUSTRIES (FR) 1978-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279215-A1 NAMPT MODULATORS NAMPT, SIRT1, NNT LOXL2 3854/4885LMNA 798/4885CYP1A2 2623/4885
US-11530226-B2 Azepane inhibitors of menin-MLL interaction MEN1, MLLT1, BMI1 LOXL2 2362/4885LMNA 1242/4885CYP1A2 4393/4885
US-20250163049-A1 FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS USP1, USP2, SUMO1 LOXL2 2449/4885LMNA 3727/4885CYP1A2 3269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.